+ Watch NVO
on My Watchlist
Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.
1.) The P/E, P/B, P/CF, and P/S might not be pretty, but compare that to the overall industry and the concerns vanish. Especially with a fair value picked from $210 by Seeking Alpha and $222 by Morningstar.2.) A solid moat with a large portfolio of successful drugs, although Tresiba might not be released to the U.S until past 2017, giving Sanofi some time to chip away. But...3.) A Morningstar Stewardship Grade of "Exemplary". They were also ranked among the most innovative companies by Forbes magazine. As it is stated in Walter Issacson's biography of Steve Jobs: "The mark of an innovative company is not only that it comes up with new ideas first. It also knows how to leapfrog when it finds itself behind." If only one company has the right leadership in this, it's Novo. Not convinced they're good enough? Try a 94% approval rating of the CEO on Glassdoor.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions